Citations

Clear

46 citation(s) found for "Vasquez, F".

Abstract 12754: Infused CD34 Cell Dose, not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients With Left Ventricular Dysfunction post STEMI: Results of the PreSERVE-AMI Trial
Kereiakes, Dean J. , Shavelle, David M. , Henry, Timothy D. , Toma, Catalin , Barsness, Gregory W. , Frohwein, Steve, Schatz, Richartd A, Cohen, Martin, Davidson, Charles J., Klapholz, Marc, Schaer, Gary L. , Moss, Thomas J. , Kanakaraj, AnnaMaria, Druker, Vitaly , Harper, Ken, Chung, Amy M. , Junge, Candice, Preti, Robert A., Smith, Robin L., Mazzo, David J., Pecora, Andrew L. , Quyyumi, Arshed A. , Abdel‐Latif, Ahmed , Schatz, R A, Dib, Nabil , Vásquez, Alejandro Arias , Kanakaraj, Anna Maria, Harper, Ken, Chung, Amy, Mazzo, David J., Losordo, Douglas W.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.12754 Get It

Background: Prior studies suggest an association between naturally high circulating levels of CD34+ cells (CD34) and better outcomes following ischemic events. Pts in the treatment arm of the PreSERVE-AMI study were infused with all CD34 yielded from their bone marrow harvest, resulting in pts with naturally higher CD34 cell counts being infused with a higher cell dose. To determine whether selection bias may have influenced results, we performed an analysis of the relationship between BM CD34 content and outcomes in PreSERVE-AMI. Methods: PreSERVE-AMI is a Phase 2, randomized, double-blind, placebo-controlled trial of autologous, BM derived CD34 (CLBS10) in pts with LV dysfunction (LVEF ≤48% by MRI) ≥4 days post-STEMI. All pts underwent mini BM harvest and were randomized 1:1 to intracoronary infusion of CD34 (minimum dose 10M±20% cells) or placebo (cell diluent). Primary safety endpoints included AEs, SAEs and MACE (CV mortality, HF hospitalization, reinfarction, revascularization). Secondary endpoints included LVEF change from baseline. Regression analyses were performed to assess the influence of BM CD34 content on outcomes. Results: 161 patients were randomized and received intracoronary infusion (Jan 2013-Dec 2014). Mean age was 57±10 and 82% were men. Mean follow-up time was 18 mo, and safety data are accruing. BM CD34 content was not associated with differences in baseline characteristics with the exception of diabetes prevalence being higher in those with higher BM CD34 count (p=0.03). In controls, regression analyses showed no association of BM CD34 content with rates of MACE (p=0.2), SAEs (p=0.4), or change in LVEF (p=0.9). However, in CD34 treated pts, there was a dose-dependent improvement in LV function (p=0.045) and dose-dependent trends in MACE and SAE reduction compared to controls. As previously reported SPECT perfusion improved to a similar degree in control and treated pts. Conclusions: These data suggest that intracoronary infusion of CD34 cells, rather than BM CD34 cell content, is responsible for the benefit observed in the CD34 treatment group. The finding of a dose-response relationship is an important advance for defining the CD34 as an active agent for tissue repair. Future studies will further define CD34 dosimetry.
Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study
Vasquez, Alejandra , Farias‐Moeller, Raquel , Sánchez-Fernández, Iván, Amengual‐Gual, Marta , Anderson, Anne E. , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Gaillard, William D , Mikati, Mohamad A , Morgan, Lindsey A , Abend, Nicholas S. , Arya, Ravindra , Glauser, Tracy A. , Guerriero, Rejean M , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Pediatric Critical Care Medicine | June 14, 2021 | Volume: 22 | Issue: 12 | Pages: e613-e625

10.1097/pcc.0000000000002786 | PMID 34120133 Get It

OBJECTIVES: To characterize the pediatric super-refractory status epilepticus population by describing treatment variability in super-refractory status epilepticus patients and comparing relevant clinical characteristics, including outcomes, between super-refractory status epilepticus, and nonsuper-refractory status epilepticus patients. DESIGN: Retrospective cohort study with prospectively collected data between June 2011 and January 2019. SETTING: Seventeen academic hospitals in the United States. PATIENTS: We included patients 1 month to 21 years old presenting with convulsive refractory status epilepticus. We defined super-refractory status epilepticus as continuous or intermittent seizures lasting greater than or equal to 24 hours following initiation of continuous infusion and divided the cohort into super-refractory status epilepticus and nonsuper-refractory status epilepticus groups. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We identified 281 patients (157 males) with a median age of 4.1 years (1.3–9.5 yr), including 31 super-refractory status epilepticus patients. Compared with nonsuper-refractory status epilepticus group, super-refractory status epilepticus patients had delayed initiation of first nonbenzodiazepine-antiseizure medication (149 min [55–491.5 min] vs 62 min [33.3–120.8 min]; p = 0.030) and of continuous infusion (495 min [177.5–1,255 min] vs 150 min [90–318.5 min]; p = 0.003); prolonged seizure duration (120 hr [58–368 hr] vs 3 hr [1.4–5.9 hr]; p < 0.001) and length of ICU stay (17 d [9.5–40 d] vs [1.8–8.8 d]; p < 0.001); more medical complications (18/31 [58.1%] vs 55/250 [22.2%] patients; p < 0.001); lower return to baseline function (7/31 [22.6%] vs 182/250 [73.4%] patients; p < 0.001); and higher mortality (4/31 [12.9%] vs 5/250 [2%]; p = 0.010). Within the super-refractory status epilepticus group, status epilepticus resolution was attained with a single continuous infusion in 15 of 31 patients (48.4%), two in 10 of 31 (32.3%), and three or more in six of 31 (19.4%). Most super-refractory status epilepticus patients (30/31, 96.8%) received midazolam as first choice. About 17 of 31 patients (54.8%) received additional treatments. CONCLUSIONS: Super-refractory status epilepticus patients had delayed initiation of nonbenzodiazepine antiseizure medication treatment, higher number of medical complications and mortality, and lower return to neurologic baseline than nonsuper-refractory status epilepticus patients, although these associations were not adjusted for potential confounders. Treatment approaches following the first continuous infusion were heterogeneous, reflecting limited information to guide clinical decision-making in super-refractory status epilepticus.
Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort)
Sculier, Claudine , Aguilar, Cristina Barcia , Gaspard, Nicolas , Gaínza‐Lein, Marina , Fernández, Iván Sánchez , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Burrows, Brian T., Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , Gorman, Mark , McDonough, Tiffani L. , Mikati, Mohamad A. , Nayak, Anuranjita , Peariso, Katrina , Riviello, James J. , Rusie, Allison, Sperberg, Katherine , Stredny, Coral M. , Tasker, Robert C. , Vasquez, Alejandra , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, pSERG, Barcia Aguilar, Cristina , Sánchez Fernández, Iván , Lai, Yi-Chen , Mikati, Mohamad A , Arya, Ravindra , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Gaspard, Nicolas , Gaillard, William D , Glauser, Tracy A. , Lai, Yi‐Chen , Tchapyjnikov, Dmitry , Loddenkemper, Tobias , pSERG

Mayo Clinic

Epilepsia | June 7, 2021 | Volume: 62 | Issue: 7 | Pages: 1629-1642

10.1111/epi.16950 | PMID 34091885 Get It

AbstractObjectiveWe aimed to characterize the clinical profile and outcomes of new onset refractory status epilepticus (NORSE) in children, and investigated the relationship between fever onset and status epilepticus (SE).MethodsPatients with refractory SE (RSE) between June 1, 2011 and October 1, 2016 were prospectively enrolled in the pSERG (Pediatric Status Epilepticus Research Group) cohort. Cases meeting the definition of NORSE were classified as "NORSE of known etiology" or "NORSE of unknown etiology." Subgroup analysis of NORSE of unknown etiology was completed based on the presence and time of fever occurrence relative to RSE onset: fever at onset (≤24 h), previous fever (2 weeks–24 h), and without fever.ResultsOf 279 patients with RSE, 46 patients met the criteria for NORSE. The median age was 2.4 years, and 25 (54%) were female. Forty (87%) patients had NORSE of unknown etiology. Nineteen (48%) presented with fever at SE onset, 16 (40%) had a previous fever, and five (12%) had no fever. The patients with preceding fever had more prolonged SE and worse outcomes, and 25% recovered baseline neurological function. The patients with fever at onset were younger and had shorter SE episodes, and 89% recovered baseline function.SignificanceAmong pediatric patients with RSE, 16% met diagnostic criteria for NORSE, including the subcategory of febrile infection‐related epilepsy syndrome (FIRES). Pediatric NORSE cases may also overlap with refractory febrile SE (FSE). FIRES occurs more frequently in older children, the course is usually prolonged, and outcomes are worse, as compared to refractory FSE. Fever occurring more than 24 h before the onset of seizures differentiates a subgroup of NORSE patients with distinctive clinical characteristics and worse outcomes.
CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity
Ernst, Michelle, Baugh, Evan H., Thomas‐Wilson, Amanda , Bier, Louise , Lippa, Natalie , Stong, Nicholas , Mulhern, Maureen , Kushary, Sulagna , Akman, Cigdem I. , Heinzen, Erin L. , Yeh, Raymond, He, Weimin , Hanchard, Neil A. , Burrage, Lindsay C. , Leduc, Magalie S. , Chong, Josephine S. C., Bend, Renee, Lyons, Michael J. , Lee, Jennifer A. , Suwannarat, Pim, Brilstra, Eva H. , Simon, Marleen, Binsbergen, Ellen van , Groepper, Daniel , Fleischer, Julie , Keren, Boris , Mignot, Cyril , Mathieu, Sophie , Mancini, Grazia M.S. , Madan‐Khetarpal, Suneeta, Infante, Elena , Bluvstein, Judith , Seeley, Andrea , Bachman, Kristine , Klee, Eric W. , Schultz‐Rogers, Laura , Hasadsri, Linda , Barnett, Sarah , Ellingson, Marissa S. , Ferber, Matthew J. , Ramsey, Keri , Rauch, Anita , Joset, Pascal , Steindl, Katharina , Sheehan, Theodore , Vasquez, Alejandra , Ruivenkamp, Claudia , White, Susan M. , Monaghan, Kristin G. , Goldstein, David B. , Sands, Tristan T. , Aggarwal, Vimla S. , Ernst, Michelle E , Schultz-Rogers, Laura E, Sheehan, Theodore , Poduri, Annapurna , Sands, Tristan T , Rauch, Anita , Burrage, Lindsay C , Stong, Nicholas , Yeh, Raymond, Koopmans, Marion , Nava, Caroline , Narayanan, Vinodh , Pais, Lynn

Mayo Clinic

Epilepsia | May 27, 2021 | Volume: 62 | Issue: 7 | Pages: No page available

10.1111/epi.16931 | PMID 34041744 Get It

AbstractCSNK2B has recently been implicated as a disease gene for neurodevelopmental disability (NDD) and epilepsy. Information about developmental outcomes has been limited by the young age and short follow‐up for many of the previously reported cases, and further delineation of the spectrum of associated phenotypes is needed. We present 25 new patients with variants in CSNK2B and refine the associated NDD and epilepsy phenotypes. CSNK2B variants were identified by research or clinical exome sequencing, and investigators from different centers were connected via GeneMatcher. Most individuals had developmental delay and generalized epilepsy with onset in the first 2 years. However, we found a broad spectrum of phenotypic severity, ranging from early normal development with pharmacoresponsive seizures to profound intellectual disability with intractable epilepsy and recurrent refractory status epilepticus. These findings suggest that CSNK2B should be considered in the diagnostic evaluation of patients with a broad range of NDD with treatable or intractable seizures.
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (
Albain, Kathy S. , Hayes, Daniel F. , Perez, Edith A. , Goldstein, Lori J. , Chia, Stephen , Dhesy-Thind, Subkhbinder, Rastogi, Priya , Gil, Miguel Gil, Arce-Salinas, Claudia , Pierga, Jean‐Yves , Lluch, Ana Hernandez, Vasquez, Manuel Ramos, Borrego, Manuel Ruíz, Ferrero, Jean-­Marc , Schott, Anne F. , Shak, S., Lew, Danika L., Miao, Jieling, Dhesy‐Thind, Sukhbinder , Dhesy-Thind, Sukhbinder , Kalinsky, Kevin M. , Barlow, William E. , Meric‐Bernstam, Funda , Gralow, Julie R. , Lin, Nancy U. , Alba, Emilio , Delaloge, Suzette , Martín, Miguel , Brain, Etienne G.C. , Park, In Hae , Jung, Kyung Hae , Sharma, Priyanka , Miao, Jieling , Tripathy, Debu , Hortobágyi, Gabriel N. , Pusztai, Lajos

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: GS3-00-GS3-00

10.1158/1538-7445.sabcs20-gs3-00 Get It

Abstract Funding: Supported by National Cancer Institute grants U10CA180888, U10CA180819, U10CA180820, U10CA180821, U10CA180868, U10CA180863; and in part by Susan G. Komen for the Cure® Research Program, The Hope Foundation for Cancer Research, Breast Cancer Research Foundation, and Genomic Health, Inc. Acknowledgement: The authors wish to thank Dr. Ana M. Gonzalez-Angulo, MD, for her invaluable contributions to the design and implementation of this study. Background: The clinical utility of the RS to determine CT benefit is well established in pts with HR+, HER2-, axillary lymph node (LN)-negative BC. Retrospective analyses from SWOG S8814 support the potential prognostic and predictive role of RS for CT benefit in postmenopausal pts with LN+ BC. SWOG S1007 is a prospective, randomized trial of endocrine therapy (ET) vs. chemoendocrine therapy (CET) in women with 1-3 +LN and a RS &lt; 25 (NCT01272037). Methods: Eligibility criteria included women &gt; 18 years of age with HR+, HER2- BC and 1-3 +LN and no contraindications to taxane and/or anthracycline based CT. Women with a RS &lt; 25 were randomized to receive ET or CET in 1:1 randomization using 3 stratification factors: (1) RS (0-13 vs.14-25); (2) menopausal status; and (3) axillary nodal dissection vs. sentinel node biopsy. The primary objective was to determine the effect of CT on invasive disease-free survival (IDFS) and whether the effect depended on the RS. The primary analysis was to test for a significant interaction of the treatment arm and continuous RS using a Cox regression model for IDFS, adjusting for treatment, RS, and menopausal status. A total of 832 IDFS events were expected for the final analysis. Secondary objectives included overall survival (OS). The protocol specified that interaction between treatment and the stratification variables was to be tested and, if significant, separate analyses performed by stratum. Annual interim analyses were planned starting at 24% of events. At the third interim analysis with 410 IDFS events, the Data and Safety Monitoring Committee recommended reporting results, with a decision by the NCI’s Cancer Therapy Evaluation Program, the study sponsor. Results: Of the 9,383 women screened from 2/28/11-9/29/17, 5,083 pts (54.2%) were randomized. With a median follow-up of 5.1 years, 447 IDFS events have been observed. For the primary analysis, the interaction test for CT benefit and continuous RS was not statistically significant, p=0.30. In a model with CT, RS, and menopausal status (no interaction term), higher continuous RS was associated with worse IDFS [HR 1.06, 2-sided p&lt;0.001, 95% Confidence Interval (CI) 1.04-1.07], and CT was associated with an improvement in IDFS (HR 0.81, p=0.026, 95% CI 0.67-0.98). In a pre-specified analysis, a significant interaction was identified between CT and menopausal status (p=0.004), necessitating separate analyses by menopausal status. In postmenopausal pts (N=3350, 67%), adjusting for continuous RS, the HR for CET vs. ET was not significant (HR=0.97, p=0.82, 95% CI 0.78-1.22; 5-year IDFS 91.6% vs. 91.9%) indicating no benefit from CT. In premenopausal pts (N=1665, 33%), the HR (0.54) was statistically significant (p=0.0004, 95% CI 0.38-0.76; 5-year IDFS 94.2% vs. 89.0%), indicating CT benefit. In premenopausal pts, ovarian suppression was performed in 15.9% vs. 3.7% (ET vs. CET), and 47.9% vs. 26.4% reported menstruation after 6 months of treatment. Although the number of events is limited, the HR for treatment adjusted by RS for OS in premenopausal pts was 0.47 (p=0.032, 95% CI 0.24-0.94). At this time, there is no differential effect with CT in regard to other stratification factors. Conclusions: There is a significant differential treatment effect of CT benefit based on RS for premenopausal vs. postmenopausal women requiring separate analyses. While only 54% of the protocol specified events are recorded and pts will be followed for 15 years, the current data show that adjuvant therapy can be de-escalated to ET alone in postmenopausal pts with a RS &lt; 25 and 1-3 +LN. However, there is a strong IDFS benefit for CET in premenopausal pts, with an early indication of an OS improvement. Citation Format: Kevin Kalinsky, William E Barlow, Funda Meric-Bernstam, Julie R Gralow, Kathy S Albain, Daniel Hayes, Nancy Lin, Edith A Perez, Lori J Goldstein, Stephen Chia, Subkhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Miguel Martín, Miguel Gil Gil, Claudia Arce-Salinas, Etienne Brain, In Hae Park, Jean-Yves Pierga, Ana Hernandez Lluch, Manuel Ramos Vasquez, Manuel Ruiz Borrego, Kyung Hae Jung, Jean-Marc Ferrero, Anne Schott, Steve Shak, Priyanka Sharma, Danika L Lew, Jieling Miao, Debu Tripathy, Gabriel Hortobagyi, Lajos Pusztai. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) &lt; 25: SWOG S1007 (RxPonder) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr GS3-00.
A multi-institutional review of endovenous thermal ablation of the saphenous vein finds male sex and use of anticoagulation are predictors of long-term failure
Erben, Young , Vasquez, Isabel, Li, Yupeng , Gloviczki, Péter , Kalra, Manju , Martino, Randall R. De , Bjarnason, Haraldur , Neisen, Melissa , Moore, January , Rocha-Franco, Joao A. Da, Sanchez-Valenzuela, Maria C., Frey, G. , Toskich, Beau , Devcic, Zlatko , Farres, Houssam , Oldenburg, W. A., Gomez-Perez, Jessica, Yarbrough, Justin, Adalia, Michael, Stone, William M., Meltzer, Andrew J., Hakaim, Albert G., Oderich, Gustavo, De Martino, Randall R, Neisen, Melissa J, Moore, January F, Da Rocha-Franco, Joao A, Oldenburg, Warren A, Yarbrough, Justin R, Stone, William, Bjarnason, Haraldur , Oderich, Gustavo S. , Gloviczki, Péter

Mayo Clinic

Phlebology: The Journal of Venous Disease | November 12, 2020 | Volume: 36 | Issue: 4 | Pages: 283-289

10.1177/0268355520972923 | PMID 33176592 Get It

Background To review long-term outcomes and saphenous vein (SV) occlusion rate after endovenous ablation (EVA) for symptomatic varicose veins. Methods A review of our EVA database (1998–2018) with at least 3-years of clinical and sonographic follow-up. The primary end point was SV closure rate. Results 542 limbs were evaluated. 358 limbs had radiofrequency and 323 limbs had laser ablations; 542 great saphenous veins (GSV), 106 small saphenous veins (SSV) and 33 anterior accessory saphenous veins (AASV) were treated. Follow-up was 5.6 ± 2.3 years; 508 (74.6%) veins were occluded, 53 (7.8%) partially occluded and 120 (17.6%) were patent. On multivariable Cox regression analysis, male sex (HR 1.6, 95% CI [0.46–018], p = 0.012) and use anticoagulation (HR 2.0, 95% CI [0.69–0.34], p = 0.044) were predictors of long-term failure. On Kaplan-Meier curve, we had an 86.3% occlusion rate. Conclusion Our experience revealed a 5-year closure rate of 86.3%. Ablations have satisfactory occlusion rate.
First-line medication dosing in pediatric refractory status epilepticus
Vasquez, Alejandra , Gaínza‐Lein, Marina , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Riviello, James J. , Sannagowdara, Kumar , Tasker, Robert C. , Tchapyjnikov, Dmitry , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Kelley, Sarah A. , Stafstrom, Carl E. , Kossoff, Eric H. , Lewis, Dalila, Stanfield, Tony, Sculier, Claudine , Sansevere, Arnold J. , Sacco, Melissa, Duncan, Abby, McCoy, Jordan, DaSilva-Chiodo, Kathryn, Faist, Robert, Santel, D., LaFay, Victor , Clark, Peggy O., Borror, Sarah, Debs, Andrea, Clohessy, Caitlin, Weber, Amanda , Yuliati, Asri, Luat, Aimée F. , Singh, Azara, Helseth, Ashley , Fernandes, Cecilia, Tran, Linh , McLean, Melissa, Nayak, Anuranjita , Hecox, Kurt, Nallamothu, R. K., Rehborg, Rebecca, Goldstein, David B., Cox, Erin Heinzen, Malone, Colin D., Thornburg, Olivia , Basma, Natasha, Burrows, Brian T., Dyar, Beata, Mishler, Laura, Lee‐Eng, Jacqueline , Streb, Madison, Ganesan, Saptharishi Lalgudi , Huh, Linda , Martic, Nela, Abend, Nicholas S. , Amengual-Gual, Marta, Anderson, Anne, Arya, Ravindra , Brenton, J Nicholas , Farias-Moeller, Raquel, Glauser, Tracy, Goldstein, Joshua L, Guerriero, Rejean M , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J , Payne, Eric T , Tasker, Robert C , Tchapyjnikov, Dmitry , Wainwright, Mark S , Wilfong, Angus, Loddenkemper, Tobias , Gaillard, William D , Mikati, Mohamad A , Morgan, Lindsey A , Glauser, Tracy A. , Novotny, Edward J. , Bansal, Seema, Habela, Christa Whelan , Aguilar, Cristina Barcia , Santel, Daniel, LaFay, Victor, Turner, David A. , Nallamothu, Rupa, Grinspan, Zachary M. , Appavu, Brian , Hahn, Cecil D.

Mayo Clinic

Neurology | September 11, 2020 | Volume: 95 | Issue: 19 | Pages: No page available

10.1212/wnl.0000000000010828 | PMID 32913024 Get It

Retrospective observational study on hospital readmission for status epilepticus in the United States over 2016
Amengual‐Gual, Marta , Fernández, Iván Sánchez , Vasquez, Alejandra , Loddenkemper, Tobias , Sánchez Fernández, Iván , Loddenkemper, Tobias

Mayo Clinic

Epilepsia | July 19, 2020 | Volume: 61 | Issue: 7 | Pages: 1386-1396

10.1111/epi.16586 | PMID 32683696 Get It

AbstractObjectiveDescribe hospital readmission for status epilepticus (SE) in the United States, and study potential risk factors for readmission.MethodsThis is a retrospective observational study using the Healthcare Cost and Utilization Project's 2016 Nationwide Readmissions Database. We studied patients of all ages admitted to the hospital due to SE.ResultsWe included 32 327 patients admitted for SE in 2016. 8.4% of these patients were readmitted for SE at least one more time within 2016 (cross‐sectional analysis). The incidence rate was 18 readmissions for SE per 1000 patient‐months. Among the survivors of the index admission for SE who had at least 6 months of follow‐up within this database (16 043 patients), the cumulative probability of having a readmission for SE at 1, 3, and 6 months from the index admission was approximately 3.5%, 7.5%, and 11%, respectively (time‐to‐event analysis). Patients with refractory epilepsy were more likely to have a readmission for SE compared to patients without refractory epilepsy (hazard ratio [HR] 1.49, 95% confidence interval [CI] 1.23‐1.82, adjusted P =.0006), and pediatric patients were more likely to have a readmission for SE compared to adult patients (HR 1.53, 95% CI 1.26‐1.87, adjusted P = .0003) during 6‐month follow‐up.SignificanceHospital readmissions for SE in the United States are frequent. Independent factors associated with readmission in this database were refractory epilepsy and pediatric age.
Multimodal Breast Phantoms for Microwave, Ultrasound, Mammography, Magnetic Resonance and Computed Tomography Imaging
Ruvio, Giuseppe , Solimene, Raffaele , Cuccaro, Antonio , Fiaschetti, Gaia, Fagan, Andrew , Cournane, Seán , Cooke, Jennie , Ammann, Max J. , Vasquez, J. A. Tobón , Browne, Jacinta E. , Fagan, Andrew J , Tobon, Jorge , Browne, Jacinta

Mayo Clinic

Sensors | April 23, 2020 | Volume: 20 | Issue: 8 | Pages: 2400

10.3390/s20082400 | PMID 32340281 Get It

The aim of this work was to develop multimodal anthropomorphic breast phantoms suitable for evaluating the imaging performance of a recently-introduced Microwave Imaging (MWI) technique in comparison to the established diagnostic imaging modalities of Magnetic Resonance Imaging (MRI), Ultrasound (US), mammography and Computed Tomography (CT). MWI is an emerging technique with significant potential to supplement established imaging techniques to improve diagnostic confidence for breast cancer detection. To date, numerical simulations have been used to assess the different MWI scanning and image reconstruction algorithms in current use, while only a few clinical trials have been conducted. To bridge the gap between the numerical simulation environment and a more realistic diagnostic scenario, anthropomorphic phantoms which mimic breast tissues in terms of their heterogeneity, anatomy, morphology, and mechanical and dielectric characteristics, may be used. Key in this regard is achieving realism in the imaging appearance of the different healthy and pathologic tissue types for each of the modalities, taking into consideration the differing imaging and contrast mechanisms for each modality. Suitable phantoms can thus be used by radiologists to correlate image findings between the emerging MWI technique and the more familiar images generated by the conventional modalities. Two phantoms were developed in this study, representing difficult-to-image and easy-to-image patients: the former contained a complex boundary between the mammary fat and fibroglandular tissues, extracted from real patient MRI datasets, while the latter contained a simpler and less morphologically accurate interface. Both phantoms were otherwise identical, with tissue-mimicking materials (TMMs) developed to mimic skin, subcutaneous fat, fibroglandular tissue, tumor and pectoral muscle. The phantoms’ construction used non-toxic materials, and they were inexpensive and relatively easy to manufacture. Both phantoms were scanned using conventional modalities (MRI, US, mammography and CT) and a recently introduced MWI radar detection procedure called in-coherent Multiple Signal Classification (I-MUSIC). Clinically realistic artifact-free images of the anthropomorphic breast phantoms were obtained using the conventional imaging techniques as well as the emerging technique of MWI.
The genetic architecture of the human cerebral cortex
Grasby, Katrina L. , Jahanshad, Neda , Painter, Jodie N. , Colodro‐Conde, Lucía , Bralten, Janita , Hibar, Derrek P. , Lind, Penelope A. , Pizzagalli, Fabrizio , Ching, Christopher R. K. , McMahon, Mary , Shatokhina, Natalia , Zsembik, Leo , Thomopoulos, Sophia I. , Zhu, Alyssa H. , Strike, Lachlan T. , Alhusaini, Saud , Almeida, Marcio , Amlien, Inge K. , Andersson, Micael , Ard, Tyler , Armstrong, Nicola J. , Bernard, Manon , Brouwer, Rachel M. , Buimer, Elizabeth E.L. , Bürger, Christian, Cannon, Dara M. , Chen, Qiang , Cheung, J. , Couvy‐Duchesne, Baptiste , Dale, Anders M. , Dalvie, Shareefa , Araujo, Tânia Kawasaki de , Zubicaray, Greig I. de , Zwarte, Sonja M. C. de , Braber, Anouk den , Doan, Nhat Trung , Dohm, Katharina , Ehrlich, Stefan , Engelbrecht, Hannah-Ruth , Erk, Susanne , Fan, Chun Chieh , Fedko, Iryna O. , Foley, Sonya , Fukunaga, Masaki , Ge, Tian , Giddaluru, Sudheer, Goldman, Aaron L. , Green, Melissa J. , Groenewold, Nynke A. , Grotegerd, Dominik , Gurholt, Tiril P. , Hansell, Narelle K. , Harris, Mathew A., Harrison, Marc , Haswell, Courtney C. , Hauser, Michael A. , Heslenfeld, Dirk J., Ho, New Fei , Hoehn, David , Holleran, Laurena , Hottenga, Jouke‐Jan , Jansen, Iris E. , Jockwitz, Christiane , Karama, Sherif , Kasperavičiūtė, Dalia , Kaufmann, Tobias , Kelly, Sinéad, Kikuchi, Masataka , Klein, Marieke , Knapp, Michael , Knodt, Annchen R. , Krämer, Bernd , Lancaster, T. , Lewis, Lindsay B. , Mathias, Samuel R. , Melzer, Tracy R. , Milaneschi, Yuri , Mirza‐Schreiber, Nazanin , Moreira, José C.V. , Mühleisen, Thomas W. , Müller‐Myhsok, Bertram , Najt, Pablo , Nakahara, Soichiro , Orfanos, Dimitri Papadopoulos , Pitcher, Toni L. , Quidé, Yann , Ragothaman, Anjanibhargavi , Reay, William R. , Redlich, Ronny , Repple, Jonathan , Riedel, Brandalyn C. , Risacher, Shannon L. , Rocha, Cristiane S. , Salminen, Lauren E. , Saremi, Arvin , Schlag, Fenja, Schmaal, Lianne , Secolin, Rodrigo , Shapland, Chin Yang , Shumskaya, Elena , Sønderby, Ida E. , Sprooten, Emma , Tansey, Katherine E. , Teumer, Alexander , Thalamuthu, Anbupalam , Tordesillas‐Gutiérrez, Diana , Turner, Jessica A. , Uhlmann, Anne , Meer, Dennis van der , Donkelaar, Marjolein M. J. van , Eijk, Liza van , Haren, Neeltje E.M. van , Tol, Marie‐José van , Walton, Esther , Wang, Mingyuan, Wardlaw, Joanna M. , Wen, Wei , Whelan, Christopher D. , Wittfeld, Katharina , Wolf, Christiane , Wolfers, Thomas , Wu, Jing , Yasuda, Clarissa Lin , Zaremba, Dario , Zhang, Zuo , Zwiers, Marcel P. , Artiges, Éric , Assareh, Amelia A., Ayesa‐Arriola, Rosa , Belger, Ayşenil , Brandt, Christine L., Brown, Gregory G. , Cichon, Sven , Curran, Joanne E. , Davies, Gareth E., Degenhardt, Franziska , Dennis, Michelle F. , Dietsche, Bruno, Doherty, Colin P. , Espiritu, Ryan, Gowland, Penny , Häusler, Alexander N. , Heindel, Walter , Ho, Beng‐Choon , Holsboer, Florian , Hosten, Norbert , Jang, MiHyun , Jansen, Andreas , Koops, Sanne, Krug, Axel , Lim, Kelvin O. , Luykx, Jurjen J. , Mather, Karen A. , Mattay, Venkata S. , Son, Jacqueline Mayoral-van , McEwen, Sarah , Melle, Ingrid , Morris, Derek W. , Nöthen, Markus M. , OʼLeary, Daniel S. , Martinot, Marie‐Laure Paillère , Preda, Adrian , Quinlan, Erin Burke , Rasser, Paul E. , Reppermund, Simone , Steen, Vidar M. , Tooney, Paul A. , Torres, Fábio R. , Veltman, Dick J. , Voyvodic, James , White, Tonya , Yamamori, Hidenaga , Adams, Hieab H.H. , Bis, Joshua C. , Debette, Stéphanie , DeCarli, Charles , Fornage, Myriam , Guðnason, Vilmundur , Hofer, Edith , Ikram, M. Arfan , Longstreth, W.T. , Roshchupkin, Gennady V. , Satizábal, Claudia L. , Schmidt, Reinhold, Initiative¶, Alzheimer’s Disease Neuroimaging, Initiative¶, Parkinson’s Progression Markers, Alvim, Marina K. M. , Ames, David, Anderson, Tim , Blangero, John , Brodaty, Henry , Brunner, Han G. , Buckner, Randy L. , Buitelaar, Jan K. , Cairns, Murray J. , Calhoun, Vince D. , Caseras, Xavier , Caspers, Svenja , Cavalleri, Gianpiero L. , Cendes, Fernando , Corvin, Aiden , Crespo‐Facorro, Benedicto , Dalrymple‐Alford, John C. , Geus, Eco J. C. de , Deary, Ian J. , Delanty, Norman, Depondt, Chantal, Desrivières, Sylvane , Donohoe, Gary , Fisher, Simon E. , Flor, Herta , Forstner, Andreas J. , Francks, Clyde , Franke, Barbara , Glahn, David C., Gruber, Oliver , Hariri, Ahmad R. , Hartman, Catharina A. , Hashimoto, Ryota , Heinz, Andreas , Hillegers, Manon H. J. , Hoekstra, Pieter J. , Hong, L. Elliot , Pol, Hilleke E. Hulshoff , Jönsson, Erik G. , Kahn, René S. , Kennedy, Martin A. , Kircher, Tilo , Hellard, Stéphanie Le , Loughland, Carmel M. , Martinot, Jean‐Luc , McMahon, Katie L. , Meyer‐Lindenberg, Andreas , Michie, Patricia T. , Morey, Rajendra A. , Mowry, Bryan , Nyberg, Lars , Oosterlaan, Jaap , Pantelis, Christos , Pausová, Zdenka , Penninx, Brenda W.J.H. , Polderman, Tinca J. C. , Posthuma, Daniëlle , Rowland, Laura M. , Sachdev, Perminder S. , Sämann, Philipp G. , Schall, Ulrich , Schumann, Günter , Scott, Rodney J. , Sim, Kang , Smoller, Jordan W., Sommer, Iris E. , Pourcain, Beaté St , Stein, Dan J. , Ent, Dennis van ‘t , Völzke, Henry , Weber, Bernd , Weinberger, Daniel R. , Wright, Margaret J. , Zhou, Juan , Thompson, Paul M. , Medland, Sarah E. , Seppi, Klaus , Duijn, Cornelia M. van , Jicha, Gregory A. , Vernooij, Meike W. , Mishra, Aniket , Saba, Yasaman , Shenkman, Elizabeth , Ghanbari, Mohsen , Knol, Maria J. , Witte, A. Veronica , Kremen, Sarah , DeCarli, Charles , McMahon, Mary Agnes B , Zsembik, Leo C P , Agartz, Ingrid , Almeida, Marcio A A , Amlien, Inge K , Andersson, Micael , Ard, Tyler , Armstrong, Nicola J , Atkins, Joshua R , Bernard, Manon , Brouwer, Rachel M , Buimer, Elizabeth E L , Chen, Qiang , Cheung, Joshua W , Couvy-Duchesne, Baptiste , Dale, Anders M , de Araujo, Tânia K , de Zubicaray, Greig I , Dohm, Katharina , Ehrlich, Stefan , Engelbrecht, Hannah-Ruth , Fedko, Iryna O , Ford, Judith M , Fukunaga, Masaki , Garrett, Melanie E , Green, Melissa J , Grotegerd, Dominik , Gurholt, Tiril P , Gutman, Boris A , Hansell, Narelle K , Harris, Mathew A , Harrison, Marc B , Haswell, Courtney C , Hauser, Michael , Herms, Stefan , Hoehn, David , Hoffmann, Per , Holleran, Laurena , Hoogman, Martine , Hottenga, Jouke-Jan , Ikeda, Masashi , Janowitz, Deborah , Jansen, Iris E , Jia, Tianye , Jockwitz, Christiane , Kanai, Ryota , Karama, Sherif , Kaufmann, Tobias , Kikuchi, Masataka , Klein, Marieke , Knodt, Annchen R , Krämer, Bernd , Lee, Phil H , Lewis, Lindsay B , Lopes-Cendes, Iscia , Luciano, Michelle , Macciardi, Fabio , Marquand, Andre F , Melzer, Tracy R , Mirza-Schreiber, Nazanin , Moreira, Jose C V , Mühleisen, Thomas W , Najt, Pablo , Olde Loohuis, Loes M , Orfanos, Dimitri Papadopoulos , Pearson, John F , Pitcher, Toni L , Quidé, Yann , Ragothaman, Anjanibhargavi , Reay, William R , Reinbold, Céline S , Repple, Jonathan , Richard, Geneviève , Riedel, Brandalyn C , Rocha, Cristiane S , Mota, Nina Roth , Salminen, Lauren , Saremi, Arvin , Saykin, Andrew J , Schlag, Fenja , Schofield, Peter R , Secolin, Rodrigo , Shapland, Chin Yang , Shen, Li , Shin, Jean , Shumskaya, Elena , Sprooten, Emma , Thalamuthu, Anbupalam , Turner, Jessica A , Vallerga, Costanza Ludovica , van Eijk, Liza , van Erp, Theo G M , van Haren, Neeltje E M , van Rooij, Daan , van Tol, Marie-José , Veldink, Jan H , Verhoef, Ellen , Walton, Esther , Wang, Mingyuan , Wang, Yunpeng , Wardlaw, Joanna Marguerite , Wen, Wei , Westlye, Lars T , Witt, Stephanie H , Wittfeld, Katharina , Wolf, Christiane , Wolfers, Thomas , Wu, Jing Qin , Yasuda, Clarissa L , Zhang, Zuo , Artiges, Eric , Ayesa-Arriola, Rosa , Belger, Aysenil , Cichon, Sven , Curran, Joanne E , Dennis, Michelle F , Djurovic, Srdjan , Doherty, Colin P , Garijo, Daniel , Gowland, Penny A , Green, Robert C. , Häusler, Alexander N , Ho, Beng-Choon , Hoffmann, Wolfgang U , Holsboer, Florian , Homuth, Georg , Hosten, Norbert , Jack, Clifford R , Jang, MiHyun , Jansen, Andreas , Krug, Axel , Lim, Kelvin O , Luykx, Jurjen J , Mathalon, Daniel H , Mattay, Venkata S , McEwen, Sarah C , Melle, Ingrid , Morris, Derek W , Mueller, Bryon A. , Nordvik, Jan E , Nöthen, Markus M , O'Leary, Daniel S , Preda, Adrian , Rasser, Paul E , Ratnakar, Varun , Steen, Vidar M , Torres, Fábio R , Veltman, Dick J , Voyvodic, James T , Whelan, Robert , Yamamori, Hidenaga , Adams, Hieab H H , López, Oscar L. , Mazoyer, Bernard , Mosley, Thomas H. , Satizabal, Claudia L , Seshadri, Sudha , Alvim, Marina K M , Anderson, Tim J , Andreassen, Ole A , Bastin, Mark E , Beckham, Jean C , Boomsma, Dorret I , Brodaty, Henry , Buitelaar, Jan K , Bustillo, Juan R , Cahn, Wiepke , Cairns, Murray J , Calhoun, Vince D. , Carr, Vaughan J , Cavalleri, Gianpiero L , Corvin, Aiden , Crespo-Facorro, Benedicto , Dalrymple-Alford, John C , Dannlowski, Udo , de Geus, Eco J C , Depondt, Chantal , Desrivières, Sylvane , Donohoe, Gary , Espeseth, Thomas , Fisher, Simon E , Flor, Herta , Francks, Clyde , Franke, Barbara , Gollub, Randy L , Håberg, Asta K , Hartman, Catharina A , Henskens, Frans A , Hillegers, Manon H J , Hoekstra, Pieter J , Holmes, Avram J , Hulshoff Pol, Hilleke E , Jönsson, Erik G , Kennedy, Martin A , Kircher, Tilo T J , Kwok, John B J , Le Hellard, Stephanie , Martin, Nicholas G , McMahon, Katie L , Meyer-Lindenberg, Andreas , Michie, Patricia T , Morey, Rajendra A , Mowry, Bryan , Oosterlaan, Jaap , Ophoff, Roel A , Pantelis, Christos , Pausova, Zdenka , Penninx, Brenda W J H , Polderman, Tinca J C , Posthuma, Danielle , Rietschel, Marcella , Roffman, Joshua L , Sachdev, Perminder S , Schall, Ulrich , Sim, Kang , Sommer, Iris E , St Pourcain, Beate , Stein, Dan J , Toga, Arthur W , Trollor, Julian N , Van der Wee, Nic J A , van 't Ent, Dennis , Walter, Henrik , Weber, Bernd , Weinberger, Daniel R , Wright, Margaret J , Zhou, Juan , Stein, Jason L , Thompson, Paul M , Medland, Sarah E , de Zwarte, Sonja M C , Ching, Christopher R K , Thomopoulos, Sophia I , Cendes, Fernando , Teumer, Alexander , van Duijn, Cornelia M , Debette, Stephanie , Seppi, Klaus , Hashimoto, Ryota , Jicha, Gregory A , Ge, Tian , Kremen, Sarah , Agartz, Ingrid , Alnæs, Dag , Ashley‐Koch, Allison E. , Bülow, Robin , Bürger, Christian, Chakravarty, M. Mallar , Dohm, Katharina , Lam, Max , Lett, Tristram A. P. , Lopes‐Cendes, Íscia , Nho, Kwangsik T. , Pütz, Benno , Rashid, Faisal M. , Saykin, Andrew J. , Schofield, Peter R. , Shen, Li , Veldink, Jan H. , Witt, Stephanie H. , Gil, Yolanda , Jack, Clifford R. , Kimbrel, Nathan A. , Kolskår, Knut K. , Matthews, Sarah , Nauck, Matthias A. , Opel, Nils , Pike, G. Bruce , Launer, Lenore J. , Mosley, Thomas H. , Seshadri, Sudha , Yang, Qiong , Initiative¶, Alzheimer’s Disease Neuroimaging, Initiative¶, Parkinson’s Progression Markers, Andreassen, Ole A. , Vásquez, Alejandro Arias , Bastin, Mark E. , Baune, Bernhard , Fernández, Guillén , Grabe, Hans Jörgen , Hopkins, William Donald , Jernigan, Terry L. , Kochunov, Peter V , Kwok, John B. , Martin, Nicholas G. , McDonald, Colm , Ophoff, Roel A. , Paus, Tomáš , Sisodiya, Sanjay , Smoller, Jordan W. , Toga, Arthur W. , Walter, Henrik , Stein, Jason L.

Mayo Clinic

Science | March 19, 2020 | Volume: 367 | Issue: 6484 | Pages: No page available

10.1126/science.aay6690 | PMID 32193296 Get It

INTRODUCTION The cerebral cortex underlies our complex cognitive capabilities. Variations in human cortical surface area and thickness are associated with neurological, psychological, and behavioral traits and can be measured in vivo by magnetic resonance imaging (MRI). Studies in model organisms have identified genes that influence cortical structure, but little is known about common genetic variants that affect human cortical structure. RATIONALE To identify genetic variants associated with human cortical structure at both global and regional levels, we conducted a genome-wide association meta-analysis of brain MRI data from 51,665 individuals across 60 cohorts. We analyzed the surface area and average thickness of the whole cortex and 34 cortical regions with known functional specializations. RESULTS We identified 369 nominally genome-wide significant loci ( P < 5 × 10 −8 ) associated with cortical structure in a discovery sample of 33,992 participants of European ancestry. Of the 360 loci for which replication data were available, 241 loci influencing surface area and 66 influencing thickness remained significant after replication, with 237 loci passing multiple testing correction ( P < 8.3 × 10 −10 ; 187 influencing surface area and 50 influencing thickness). Common genetic variants explained 34% (SE = 3%) of the variation in total surface area and 26% (SE = 2%) in average thickness; surface area and thickness showed a negative genetic correlation ( r G = −0.32, SE = 0.05, P = 6.5 × 10 −12 ), which suggests that genetic influences have opposing effects on surface area and thickness. Bioinformatic analyses showed that total surface area is influenced by genetic variants that alter gene regulatory activity in neural progenitor cells during fetal development. By contrast, average thickness is influenced by active regulatory elements in adult brain samples, which may reflect processes that occur after mid-fetal development, such as myelination, branching, or pruning. When considered together, these results support the radial unit hypothesis that different developmental mechanisms promote surface area expansion and increases in thickness. To identify specific genetic influences on individual cortical regions, we controlled for global measures (total surface area or average thickness) in the regional analyses. After multiple testing correction, we identified 175 loci that influence regional surface area and 46 that influence regional thickness. Loci that affect regional surface area cluster near genes involved in the Wnt signaling pathway, which is known to influence areal identity. We observed significant positive genetic correlations and evidence of bidirectional causation of total surface area with both general cognitive functioning and educational attainment. We found additional positive genetic correlations between total surface area and Parkinson’s disease but did not find evidence of causation. Negative genetic correlations were evident between total surface area and insomnia, attention deficit hyperactivity disorder, depressive symptoms, major depressive disorder, and neuroticism. CONCLUSION This large-scale collaborative work enhances our understanding of the genetic architecture of the human cerebral cortex and its regional patterning. The highly polygenic architecture of the cortex suggests that distinct genes are involved in the development of specific cortical areas. Moreover, we find evidence that brain structure is a key phenotype along the causal pathway that leads from genetic variation to differences in general cognitive function. Identifying genetic influences on human cortical structure. ( A ) Measurement of cortical surface area and thickness from MRI. ( B ) Genomic locations of common genetic variants that influence global and regional cortical structure. ( C ) Our results support the radial unit hypothesis that the expansion of cortical surface area is driven by proliferating neural progenitor cells. ( D ) Cortical surface area shows genetic correlation with psychiatric and cognitive traits. Error bars indicate SE. IMAGE CREDITS: (A) K. COURTNEY; (C) M. R. GLASS